company background image
0QAJ logo

DBV Technologies LSE:0QAJ Stock Report

Last Price

€0.74

Market Cap

€64.7m

7D

38.4%

1Y

-49.5%

Updated

02 Dec, 2024

Data

Company Financials +

DBV Technologies S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DBV Technologies
Historical stock prices
Current Share Price€0.74
52 Week High€2.07
52 Week Low€0.51
Beta0.86
11 Month Change-3.96%
3 Month Change-11.63%
1 Year Change-49.47%
33 Year Change-85.22%
5 Year Change-94.81%
Change since IPO-93.20%

Recent News & Updates

Recent updates

Shareholder Returns

0QAJGB BiotechsGB Market
7D38.4%1.7%-0.02%
1Y-49.5%-13.3%8.2%

Return vs Industry: 0QAJ underperformed the UK Biotechs industry which returned -13.3% over the past year.

Return vs Market: 0QAJ underperformed the UK Market which returned 8.2% over the past year.

Price Volatility

Is 0QAJ's price volatile compared to industry and market?
0QAJ volatility
0QAJ Average Weekly Movement14.4%
Biotechs Industry Average Movement7.4%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QAJ's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0QAJ's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2002108Daniel Tasséwww.dbv-technologies.com

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.

DBV Technologies S.A. Fundamentals Summary

How do DBV Technologies's earnings and revenue compare to its market cap?
0QAJ fundamental statistics
Market cap€64.66m
Earnings (TTM)-€97.02m
Revenue (TTM)€11.89m

6.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QAJ income statement (TTM)
RevenueUS$12.52m
Cost of RevenueUS$0
Gross ProfitUS$12.52m
Other ExpensesUS$114.60m
Earnings-US$102.09m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.06
Gross Margin100.00%
Net Profit Margin-815.73%
Debt/Equity Ratio0%

How did 0QAJ perform over the long term?

See historical performance and comparison